Detalhe da pesquisa
1.
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No.
Ann Oncol
; 31(9): 1112-1114, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32771305
2.
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Lung Cancer
; 187: 107427, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043395
3.
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
ESMO Open
; 8(4): 101595, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441877
4.
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
ESMO Open
; 7(2): 100455, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35398718
5.
What is the clinical impact of the LUX-Lung 5 trial?
Ann Oncol
; 27(6): 1171-1172, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26940690
6.
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.
Clin Transl Oncol
; 23(9): 1818-1826, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33728869
7.
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
ESMO Open
; 6(2): 100078, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33735802
8.
Cancer and COVID-19: Unmasking their ties.
Cancer Treat Rev
; 88: 102041, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32516704
9.
Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy.
Clin Transl Oncol
; 22(11): 2130-2135, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32232716
10.
Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.
Clin Transl Oncol
; 21(6): 790-795, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30448956
11.
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].
ESMO Open
; 7(3): 100494, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468561
12.
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078].
ESMO Open
; 6(3): 100137, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34144775
13.
The role of surgery in a case of diffuse mucormycosis with haematemesis and gastric necrosis.
Ann R Coll Surg Engl
; 96(5): e31-3, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24992411
14.
Von Hippel-Lindau and myotonic dystrophy of Steinert along with pancreatic neuroendocrine tumor and renal clear cell carcinomal neoplasm: Case report and review of the literature.
Int J Surg Case Rep
; 4(8): 648-50, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23774333
15.
Is CBOP/BEP an alternative to BEP for patients with poor prognosis metastatic germ cell tumours?
ESMO Open
; 1(4): e000089, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27843634
16.
Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.
Ann Oncol
; 15(3): 474-7, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-14998851